Gene · 5921
NIH grants2,330
NIH grants whose papers are about the gene, through NIH's grant-paper links.
341 to 360 of 2,330
Download this page as JSON| Grant | Title | RASA1 papers | Newest fiscal year |
|---|---|---|---|
| R01HL130996 | Mosaic: post-zygotic mutations in vascular malformations | 3 | 2024 |
| UL1TR001425 | Center for Clinical and Translational Science and Training | 3 | 2024 |
| P41GM103504 | National Resource for Network Biology (NRNB) | 2 | 2024 |
| R01CA244660 | Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling | 2 | 2024 |
| R01NS112819 | Reduction of Brain AVM Severity through Inhibition of Pathogenic Angiogenesis | 2 | 2024 |
| R35CA232113 | Targeting undruggable RAS for cancer treatment | 2 | 2024 |
| U01CA243004 | Multiscale analysis of metabolic inflammation as a driver of breast cancer | 2 | 2024 |
| F30GM142263 | Creating a Unified RAS Structural Nomenclature to Compare the Impact of Oncogenic Mutations on KRAS, NRAS, and HRAS | 1 | 2024 |
| I01BX002095 | Novel Functions for Ras family GTPases | 1 | 2024 |
| IK6BX004600 | BLRD Research Career Scientist Award Application | 1 | 2024 |
| K08CA252605 | Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment. | 1 | 2024 |
| P42ES017198 | Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) | 1 | 2024 |
| P50CA070907 | Targeting Lung Cancer Vulnerabilities | 1 | 2024 |
| P50CA098131 | SPORE in Breast Cancer | 1 | 2024 |
| R01AG050595 | The VETSA Longitudinal Twin Study of Cognition and Aging (VETSA 4) | 1 | 2024 |
| R01AI081759 | Enterovirus Infection of Polarized Intestinal Cells | 1 | 2024 |
| R01AI143976 | TCR signaling control of thymic Treg selection and immune homeostasis | 1 | 2024 |
| R01AI150597 | PAG is a novel target in immunotherapy | 1 | 2024 |
| R01CA179556 | Matrix density promotes pro-tumorigenic hormone actions in breast cancer | 1 | 2024 |
| R01CA188025 | Iron, Ferroptosis and Ovarian Cancer | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5921/grants?page=18